Literature DB >> 27079460

Clinical implications of a gradual dormancy concept in malaria.

Joachim Richter1, Gabriele Franken2, Martha C Holtfreter3, Susanne Walter4, Alfons Labisch2, Heinz Mehlhorn4.   

Abstract

Malaria recurrences after an initially successful therapy and malarial fever occurring a long time after infection are well-known problems in malariology. Currently, two distinct types of malaria recurrences are defined: recrudescence and relapse. A recrudescence is thought to originate from circulating Plasmodium blood stages which do not cause fever before a certain level of a microscopically detectable parasitemia is reached. Contrary, a relapse is thought to originate from quiescent intracellular hepatic parasite stages called hypnozoites. Recrudescences would typically occur in infections due to Plasmodium falciparum. Plasmodium knowlesi, and Plasmodium malariae, whereas relapses would be caused exclusively by Plasmodium vivax and Plasmodium ovale. This schematic view is, however, insufficiently supported by experimental evidence. For instance, hypnozoites of P. ovale have never been experimentally documented. On the other hand, the nonfinding of P. malariae hypnozoites turned into the proof for the nonexistence of P. malariae hypnozoites. Clinical relapse-type recurrences have been observed in both P. ovale and P. malariae infections, and decade-long incubation times have also been reported in P. falciparum infections. We propose a gradual hypothesis in accordance with the continuity concept of biological evolution: both, relapse and recrudescence may be potentially caused by all Plasmodium spp. We hypothesize that the difference between the various Plasmodium spp. is quantitative rather than qualitative: there are Plasmodium spp. which frequently cause relapses such as P. vivax, particularly the P.v. Chesson strain, species which cause relapses less frequently, such as P. ovale and sometimes P. malariae, and species which may exceptionally cause relapses such as P. falciparum. All species may cause recrudescences. As clinical consequences, we propose that 8-aminquinolines may be considered in a relapse-type recrudescence regardless of the causal Plasmodium sp., whereas primaquine relapse prevention might not be routinely indicated in malaria due to P. ovale.

Entities:  

Keywords:  Hypnozoites; Latency; Long incubation; Malaria; P. falciparum; P. knowlesi; P. malariae; P. ovale; P. vivax; Plasmodium; Recrudescence; Recurrence; Relapse

Mesh:

Substances:

Year:  2016        PMID: 27079460     DOI: 10.1007/s00436-016-5043-0

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  125 in total

1.  Drug-induced acute malaria.

Authors:  A Skoutelis; A Symeonidis; E Vassalou; H Bassaris
Journal:  Scand J Infect Dis       Date:  2000

2.  [Post-malaria neurological syndrome complicating a relapse of Plasmodium falciparum malaria after atovaquone-proguanil treatment].

Authors:  E Forestier; A Labe; D Raffenot; C Lecomte; O Rogeaux
Journal:  Med Mal Infect       Date:  2010-08-25       Impact factor: 2.152

3.  Failure of primaquine therapy for the treatment of Plasmodium ovale malaria.

Authors:  Emmanuel Bottieau; Alfons Van Gompel; Willy E Peetermans
Journal:  Clin Infect Dis       Date:  2005-11-15       Impact factor: 9.079

4.  Do hypnozoites cause relapse in malaria?

Authors:  Miles B Markus
Journal:  Trends Parasitol       Date:  2015-03-26

5.  [Transfusion malaria caused by Plasmodium ovale. A case].

Authors:  T Giacomini; F Baledent; G Hanania
Journal:  Presse Med       Date:  1988-04-23       Impact factor: 1.228

6.  Observations on early and late post-sporozoite tissue stages in primate malaria. II. The hypnozoite of Plasmodium cynomolgi bastianellii from 3 to 105 days after infection, and detection of 36- to 40-hour pre-erythrocytic forms.

Authors:  W A Krotoski; R S Bray; P C Garnham; R W Gwadz; R Killick-Kendrick; C C Draper; G A Targett; D M Krotoski; M W Guy; L C Koontz; F B Cogswell
Journal:  Am J Trop Med Hyg       Date:  1982-03       Impact factor: 2.345

7.  [The management of therapeutic failure in a falciparum malaria patient under oral arthemether-lumefantrine therapy].

Authors:  Asım Ülçay; Gökhan Karaahmetoğlu; Vedat Turhan; Hakan Erdem; Ali Acar; Oral Öncül; Levent Görenek
Journal:  Turkiye Parazitol Derg       Date:  2014

8.  P. falciparum malaria recrudescence in a cancer patient.

Authors:  E Foca; R Zulli; F Buelli; M De Vecchi; A Regazzoli; F Castelli
Journal:  Infez Med       Date:  2009-03

9.  Recrudescence of Plasmodium malariae after Quinine.

Authors:  Irfanali R Kugasia; Farhana K Polara; Hussein Assallum
Journal:  Case Rep Med       Date:  2014-02-12

10.  A comprehensive epigenome map of Plasmodium falciparum reveals unique mechanisms of transcriptional regulation and identifies H3K36me2 as a global mark of gene suppression.

Authors:  Saurabh J Pradhan; Bhagyashree Joshi; Krishanpal Karmodiya; Rahul Jangid; Puli Chandramouli Reddy; Sanjeev Galande
Journal:  Epigenetics Chromatin       Date:  2015-09-17       Impact factor: 4.954

View more
  13 in total

1.  Evaluation of Immunoglobulin G Responses to Plasmodium falciparum and Plasmodium vivax in Malian School Children Using Multiplex Bead Assay.

Authors:  Eric Rogier; Delynn M Moss; Anna N Chard; Victoria Trinies; Seydou Doumbia; Matthew C Freeman; Patrick J Lammie
Journal:  Am J Trop Med Hyg       Date:  2016-11-28       Impact factor: 2.345

2.  Antimalarial Natural Products.

Authors:  David G I Kingston; Maria Belen Cassera
Journal:  Prog Chem Org Nat Prod       Date:  2022

Review 3.  Malaria diagnostic methods with the elimination goal in view.

Authors:  Olukunle O Oyegoke; Leah Maharaj; Oluwasegun P Akoniyon; Illiya Kwoji; Alexandra T Roux; Taiye S Adewumi; Rajendra Maharaj; Bolanle T Oyebola; Matthew A Adeleke; Moses Okpeku
Journal:  Parasitol Res       Date:  2022-04-23       Impact factor: 2.383

4.  Plasmodium interspecies interactions during a period of increasing prevalence of Plasmodium ovale in symptomatic individuals seeking treatment: an observational study.

Authors:  Hoseah M Akala; Oliver J Watson; Kenneth K Mitei; Dennis W Juma; Robert Verity; Luicer A Ingasia; Benjamin H Opot; Raphael O Okoth; Gladys C Chemwor; Jackline A Juma; Edwin W Mwakio; Nicholas Brazeau; Agnes C Cheruiyot; Redemptah A Yeda; Maureen N Maraka; Charles O Okello; David P Kateete; Jim Ray Managbanag; Ben Andagalu; Bernhards R Ogutu; Edwin Kamau
Journal:  Lancet Microbe       Date:  2021-03-02

Review 5.  A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria.

Authors:  Mirjam Groger; Hannah S Fischer; Luzia Veletzky; Albert Lalremruata; Michael Ramharter
Journal:  Malar J       Date:  2017-03-11       Impact factor: 2.979

6.  Recombination events among virulence genes in malaria parasites are associated with G-quadruplex-forming DNA motifs.

Authors:  Adam Stanton; Lynne M Harris; Gemma Graham; Catherine J Merrick
Journal:  BMC Genomics       Date:  2016-11-03       Impact factor: 3.969

7.  Molecular evidence for relapse of an imported Plasmodium ovale wallikeri infection.

Authors:  Luzia Veletzky; Mirjam Groger; Heimo Lagler; Julia Walochnik; Herbert Auer; Hans-Peter Fuehrer; Michael Ramharter
Journal:  Malar J       Date:  2018-02-09       Impact factor: 2.979

8.  Polymorphism analysis of propeller domain of k13 gene in Plasmodium ovale curtisi and Plasmodium ovale wallikeri isolates original infection from Myanmar and Africa in Yunnan Province, China.

Authors:  Mengni Chen; Ying Dong; Yan Deng; Yanchun Xu; Yan Liu; Canglin Zhang; Herong Huang
Journal:  Malar J       Date:  2020-07-13       Impact factor: 2.979

9.  Molecular and cellular characterization of apoptosis in flat oyster a key mechanisms at the heart of host-parasite interactions.

Authors:  Ophélie Gervais; Tristan Renault; Isabelle Arzul
Journal:  Sci Rep       Date:  2018-08-21       Impact factor: 4.379

10.  Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting.

Authors:  Mirjam Groger; Luzia Veletzky; Albert Lalremruata; Chiara Cattaneo; Johannes Mischlinger; Rella Manego Zoleko; Johanna Kim; Anna Klicpera; Elias L Meyer; Daniel Blessborn; Markus Winterberg; Ayola A Adegnika; Selidji T Agnandji; Peter G Kremsner; Benjamin Mordmüller; Ghyslain Mombo-Ngoma; Hans-Peter Fuehrer; Michael Ramharter
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.